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Several  therapeutic  strategies were proposed  to  attempt  to 


































































































BCG induces TRAIL-dependent DC killing capacity through TLR2, 
TLR4, and TLR9 signaling. To determine which cytotoxic path-
ways were  likely  to be  involved  in  the  tumoricidal activity of 
CD11b+ TIDCs, we tested the killing activity of CD11b+ TIDCs 
Figure 1
Synergistic antitumor effect of CTX administration 
followed by intratumoral BCG injections in 2 tumor 
models. (A) Four groups of 7 wild-type BD-IX rats 
received a subcutaneous injection of 1 × 106 syn-
geneic PROb tumor cells. Rats received 1 i.p. 
injection of CTX (30 mg/kg) on day 28 after tumor 
cell injection, or 2 intratumoral injections of BCG 
(8 × 105 CFU) on day 35 and 42, or both. Con-
trol group received saline injections. Statistical 
comparison of mean tumor volume of the control 
group and treated groups was performed every 
28 days, beginning on day 56. (B) Four groups of 
8 wild-type BALB/c mice received a subcutaneous 
injection of 5 × 105 syngeneic CT26 tumor cells. 
Mice received 1 i.p. injection of CTX (100 mg/kg 
body weight) on day 7 after tumor cell injection, or 
2 intratumoral injections of BCG (8 × 104 CFU) on 
day 9 and 14, or both. Untreated mice received 
saline injections. One experiment out of 3 is 
shown. Statistical comparison of mean tumor vol-
ume of the control group and treated groups was 
performed on days 15, 20, 25, and 30. *P < 0.05; 
†P < 0.01. Un, untreated.
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CTX-BCG treatment induces tumor infiltration by myeloid DCs. (A) 
MHC-II, CD11c, TCR, and CD163 immunohistochemical labeling of 
untreated PROb tumors or tumors obtained 7 days after the last BCG 
injection in animals treated by CTX-BCG. Original magnification, ×40. 
(B) FACS analysis of the recruitment of leukocyte subpopulations (indi-
cated in horizontal line) into CT26 tumors 2 days after the last BCG 
injection. Fold increase was calculated by dividing the absolute number 
of cells found in treated animals by the absolute number of cells found 
in untreated animals. Values represent mean ± SEM. **P < 0.01.
Table 1
Immunohistochemical analyses of tumor-infiltrating inflamma-
tory cells
	 Untreated	 CTX-BCG	treated
	 Tumor	 Tumor	 Tumor	 Tumor
	 periphery	 center	 periphery	 center
Tumor cells  0 ++++ 0 +
 (12C mAb)
CD11c + + ++ +++
CD11b + ++ +++ +++
CD68 ++ ++ +++ ++++
MHC-II ++ ++ +++ ++++
CD80 0 0 + ++
CD86 0 0 ++ ++
CD163 ++ 0 + 0
TCR ++ 0 ++ +++
CD4 + + + +
CD8 + + ++ +++
CD161 + 0 + 0
Semiquantitative evaluation of antigen expression and location in tumor 
sections. Analysis was performed 7 days after the second BCG injection 
in either control or CTX-BCG–treated group. Two independent experi-
ments were performed, each on 3 individual tumors. 0, no labeled cells; 
+, 10%–20% labeled cells; ++, 20%–40% labeled cells; +++, 40%–60% 
labeled cells; ++++, 60%–80% labeled cells.
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Myeloid DCs are cytotoxic against tumor cells. (A) 
For 48 hours, 5 × 104 or 1 × 104 TIDCs or CD8+ 
T cells isolated from tumors of untreated or CTX-
BCG–treated rats were incubated with 1 × 104 
PROb cells. Cytotoxic effects on PROb cells were 
determined using a crystal violet assay. E/T, effec-
tor/target ratio. (B) For 48 hours, 5 × 104 or 1 × 104 
TIDCs or CD8+ T cells isolated from CT26 tumors 
of untreated or CTX-BCG–treated mice were incu-
bated with 1 × 104 CT26 cells for 48 hours. Cyto-
toxic effect on CT26 cells was determined using a 
crystal violet assay. (C) FACS determination of the 
absolute number of DC subpopulations induced by 
the combined treatment in the CT26 model per mg 
of tumor. CD8α+ DC, CD8α+CD11c+MHC-II+CD45+; 
CD11b+ DC, CD11b+CD11c+MHC-II+CD45+; pDC, 
Gr1+B220+NK-p46–CD11cintCD45+; IKDC, Gr1–
B220+NK–p46+CD11c+CD45+. (D) For 48 hours, 
5 × 104 or 1 × 104 CD8α+ TIDCs or CD11b+ TIDCs 
isolated from untreated or CTX-BCG–treated mice 
were incubated with 1 × 104 CT26 cells. Cytotoxic 
effect on the CT26 cells was determined using a 
crystal violet assay. For each experiment, values 
represent mean ± SEM. *P < 0.05.
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CD11b+ TIDCs or conventional DCs and the subsequent tumori-
cidal activity of TRAIL expression.






























BCG endows DCs with killing capaci-
ties via TRAIL upregulation. (A) For 48 
hours, 5 × 104 CD11b+ TIDCs isolated 
from CTX-BCG–treated mice were 
incubated with 1 × 104 CT26 cells. 
In some wells, Z-VAD-fmk (Z-VAD), 
blocking anti–Fas ligand (FasL), anti-
TRAIL mAbs, l-NMMA, or concana-
mycin A (CcmA) were added. CD11b+ 
TIDC cytotoxicity against CT26 cells 
was determined using a crystal violet 
assay. (B) FACS analysis of TRAIL 
expression on CD11b+ TIDCs (CD45+) 
that infiltrated untreated CT26 tumor 
and tumor treated with CTX-BCG. (C) 
CD11b+ TIDCs isolated from untreated 
CT26 tumors or BM-DCs were either 
untreated or cultured overnight with 
BCG (8 × 105 CFU/ml). TRAIL expres-
sion was determined by FACS analy-
sis on CD11c+ I-A/I-E+ gated cells 
and (D) 5 × 104 CD11b+ TIDCs or 
BM-DCs were incubated with 1 × 104 
CT26 cells for 48 hours. A blocking 
anti-TRAIL mAb was also added to 
some of the wells containing BM-DCs 
activated by BCG. Cytotoxic effect 
on the CT26 cells was determined 
using a crystal violet assay. (E) BM-
DCs were incubated overnight in the 
absence or presence of ligands for 
TLR2 (Pamv3CSK4 [Pam3]), TLR3 
[Poly(I:C)], TLR4 (LPS), TLR9 (CpG 
ODN 1826 [CpG 1826]), or with BCG 
(8 × 105 CFU/ml). TRAIL expression 
was determined by FACS analysis 
on CD11c+ I-A/I-E+ gated cells. (F) 
Wild-type, Myd88–/–, Tlr2–/–, Tlr4–/–, or 
wild-type mice treated with i.p. injec-
tions of TLR9 inhibitor ODN (IRS 954) 
every 3 days received a subcutaneous 
injection of 5 × 105 CT26 tumor cells. 
In the same experiment, 2 groups of 
mice received either saline or the 
combined treatment. Data represent 
mean ± SEM. *P < 0.05.
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splenic  and BM-derived DCs  can  trigger  tumor  cell  lysis  in 
vitro through NKR-P1 and nitric oxide production, respectively 
Figure 5
BCG activated human Mo-DCs are cytotoxic 
against human cell lines in a TRAIL-dependent 
manner. (A) FACS analysis of TRAIL expression 
on CD11c+ HLA-DR+ DCs derived from human 
CD14+ peripheral blood monocytes after overnight 
incubation with BCG (8 × 105 CFU/ml) or PBS. (B) 
Mo-DCs were either untreated or cultured overnight 
with BCG and then incubated with 1 × 104 HCT116 
cells for 48 hours at various effector/target ratios. 
Cytotoxic effect on HCT116 cells was determined 
using a crystal violet assay. (C) Mo-DCs were 
incubated overnight in the absence or presence of 
8 × 105 CFU/ml of BCG. Then 5 × 104 Mo-DCs were 
incubated with 1 × 104 tumor cells (M45, M96, and 
BEUR melanomas) for 48 hours and tumor cell 
cytotoxicity was determined using a crystal violet 
assay. (D) BCG stimulated Mo-DC cytotoxicity 
against HCT116 cells was determined by a crys-
tal violet assay in the presence of anti-TRAIL, 
l-NMMA, concanamycin A, and Z-VAD-fmk at a 5:1 
effector/target cell ratio. Values from 1 experiment 
out of 2 represent mean ± SEM. *P < 0.05.
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Figure 6
Tregs are selectively killed by CTX and prevent TRAIL-dependent cytotoxicity of TIDCs. (A) FACS analysis of CD4+CD25+ (Treg) cells in 
the CD3+CD4+CD127– tumor-infiltrating T cell subsets. The percentage of Tregs and dead cells in tumors were determined by DAPI labeling 
2 days after CTX injection. Numbers indicate the percentage of cells ± SD. (B) The day of the first BCG injection, 2 groups of mice were 
adoptively transferred with 1 × 106 Tregs or 1 × 106 CD4+CD25– (Tconv) cells (n = 5 in each group). (C) CD11b+ TIDCs from untreated CT26 
tumor-bearing mice were incubated overnight with BCG and with Tregs or Tconvs at a ratio 1:1. TRAIL expression was determined by FACS 
analysis. (D) Same experiment as in C but using mouse BM-DCs instead of CD11b+ TIDCs. (E) Same experiment as in D but in some wells 
DCs were separated from T cells by a 0.4-μm Transwell insert. TRAIL and GAPDH mRNA levels were determined by quantitative RT-PCR 
on CD11c cells sorted by magnetic isolation. BM-DCs incubated with IFN-γ represent a positive control of TRAIL mRNA expression. Each 
value is expressed as fold increase from medium control after normalization with GAPDH. (F) CD11b+ TIDCs from untreated CT26 tumor-
bearing animals were incubated overnight with BCG and with Tregs or Tconvs at a ratio 1:1. Then these cells (5 × 104 cells) were cultured 
with 1 × 104 CT26 cells for 48 hours. TIDC cytotoxicity on CT26 cells was determined using crystal violet staining. (G) Same experiment as 
in F but using mouse BM-DCs instead of CD11b+ TIDCs. (H) Same experiment as in F but using mouse Mo-DCs instead of CD11b+ TIDCs 
and M45 melanoma cells instead of CT26 cells. Values from 1 experiment out of 2 represent mean ± SEM. *P < 0.05.
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Treg control TRAIL-mediated antitumor effect 
of CTX-BCG treatment in vivo. (A) Unstimu-
lated or overnight BCG stimulated BM-DCs 
(1–2 × 106 cells) were injected intratumorally 
in nude mice 2, 4, 6, and 10 days after sub-
cutaneous CT26 cell injection (n = 5 in each 
group). (B) FACS analysis of TRAIL expres-
sion in CD11b+ TIDCs (CD45+) from CT26 
untreated or treated tumors. The day of the 
first BCG injection, 1 × 106 Tregs, 1 × 106 
Tconvs, or 100 μl PBS were injected intrave-
nously, and mice were killed 2 days after the 
second BCG intratumoral injection. Numbers 
indicate the percentage of cells ± SD. (C) Four 
groups of 5 BALB/c mice received a subcuta-
neous injection of 5 × 105 CT26 tumor cells. 
Seven days later, mice received the com-
bined treatment alone or in combination with 
intratumoral or i.p. injection of Z-VAD-fmk or 
anti-TRAIL mAb respectively. Untreated mice 
represent control group. For each experiment, 
animals were monitored twice a week for 
tumor volume. Values in A and C represent 
mean ± SEM. *P < 0.05.
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provided by F. Jotereau, Institut de Biologie/CHR, Nantes, France) were 
cultured in DMEM complete medium.
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